Literature DB >> 8112047

Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result.

R N Jones1, G E Zurenko.   

Abstract

The cross-resistance or cross-susceptibility of cefpodoxime and ceftriaxone for 3700 strains of Enterobacteriaceae, oxacillin-susceptible staphylococci, Streptococcus spp., Haemophilus influenzae, Moraxella catarrhalis, and Neisseria gonorrhoeae was evaluated. With the exception of tests with Enterobacter spp. and Morganella morganii, the ceftriaxone minimum inhibitory concentration (MIC) result interpretive criteria predicted bacterial susceptibility (or resistance) to cefpodoxime with an acceptable rate of serious interpretive errors (1.5%) and an absolute categorical agreement > 92%. By using cefpodoxime interpretive criteria for ceftriaxone MICs, the interpretive errors for testing enteric bacilli were reduced from 2.1% to 1.5%.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8112047     DOI: 10.1016/0732-8893(93)90041-5

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  5 in total

1.  Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.

Authors:  Ronald N Jones; John D Turnidge; Greg Moeck; Francis F Arhin; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

Review 2.  Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.

Authors:  J A Balfour; P Benfield
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

3.  Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.

Authors:  Ronald N Jones; Helio S Sader; Thomas R Fritsche; Patricia A Hogan; Daniel J Sheehan
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

Review 4.  Cefpodoxime - utility in respiratory tract infections and typhoid fever.

Authors:  Anju Aggarwal; Suman Rath
Journal:  Indian J Pediatr       Date:  2004-05       Impact factor: 1.967

5.  Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.

Authors:  Gary Zurenko; Paul Bien; Mekki Bensaci; Hina N Patel; Grace Thorne
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-09-20       Impact factor: 3.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.